Crossmark

Successes and future objectives in acute coronary syndrome

Crossref DOI link: https://doi.org/10.1038/nrcardio.2014.129

Published Online: 2014-09-02

Published Print: 2014-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

de Werf, Frans Van
License Information

Text and Data Mining valid from 2014-09-02
More Information

Article History

First Online: 2 September 2014

Competing interests

: F.V.d.W. declares that he has received research grants and fees for participating in advisory boards, data and safety monitoring boards, and speaking activities from AstraZeneca, Boehringer Ingelheim, Merck, and The Medicines Company.